Pharmaceutical manufacturers and payers have been involved in a back and forth dance regarding patient cost share practices - each action is met with a reaction. Precision's Jeremy Schafer looks at the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. Watch this on-demand webinar and Q&A moderated by Precision's Larry Blandford, as we explore these challenges, and discuss solutions to getting innovative therapies into the hands of patients who need them most.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Moderated by Precision's Kelly Wilder, join us and learn how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
Access challenges to cell and gene therapy are well documented. Precision's Christina Poschen and David Carr discuss how some innovative manufacturers are moving away from the role of being purely a researcher and manufacturer and toward involvement at the point of diagnosis through manufacturing and delivery to patient access support in order to address those challenges head on.
Who typically has responsibility for Identity and Access Management within health plan organizations, and how does this role impact or protect their healthcare analytics objectives? Precision's Dominic Galante contributes to the Thought Leaders Corner in this month's Care Analytics News.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
